证券代码：603456 证券简称：九洲药业 公告编号：2025-037 浙江九洲药业股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.30元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/18 | － | 2025/6/19 | 2025/6/19 | 差异化分红送转：是 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 8 日的2024年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 根据《中华人民共和国公司法》（以下简称"公司法"）、《中华人民共和国证券法》（以下 简称"证券法"）、《上海证券交易所上市公司自律监管指引第 ...

Group 1 - The mutual recognition arrangement between the General Administration of Customs of China and the General Customs Administration of Mongolia for AEO (Authorized Economic Operator) enterprises was officially implemented on June 1, enhancing trade facilitation between the two countries [1] - AEO enterprises will benefit from lower document review rates, reduced import inspection rates, priority inspection for goods requiring physical checks, and designated customs liaison officers to assist with customs issues [1] - Zhejiang AnDe Electric Co., Ltd., a high-end kitchen appliance manufacturer, reported a 150% year-on-year increase in exports to Mongolia, amounting to 1.99 million yuan in 2024, attributing this growth to the AEO certification and the new mutual recognition arrangement [1] Group 2 - Zhejiang Jiuzhou Pharmaceutical Co., Ltd. expressed optimism about the AEO mutual recognition arrangement, highlighting its alignment with the company's strategic goals to enhance product competitiveness and reduce international logistics costs [2] - In the first four months of this year, Zhejiang Province's trade with Mongolia reached 520 million yuan, a 39.3% increase year-on-year, with AEO enterprises in Hangzhou contributing 25.43 million yuan, a 59.6% increase [2] - The Hangzhou Customs plans to strengthen the cultivation of AEO enterprises, prioritizing certification for "Zhejiang Export Brand" companies and key industry chain enterprises to enhance their competitiveness and modern management systems [2] Group 3 - China has signed AEO mutual recognition agreements with 31 economies globally, covering 57 countries and regions, including 38 countries involved in the Belt and Road Initiative, leading the world in both the number of agreements and participating countries [3]

Group 1 - The overall market experienced a decline in the afternoon, but the pharmaceutical and medical sectors showed resilience, with only three out of 31 industries reporting gains [1] - The representative medical ETF (512170) saw a daily increase of 0.62%, with a significant trading volume of 9.82 billion, marking a 128% increase from the previous day and the highest single-day trading volume in over a month and a half [2] - The CXO-related stocks were the main contributors to the sector's performance, with notable gains from companies like Tigermed, which rose by 5.64%, while major player WuXi AppTec experienced a decline [2] Group 2 - For the week of May 19-23, the medical ETF (512170) accumulated a gain of 1.24%, outperforming major indices such as the Shanghai Composite Index, which fell by 0.57% [4] - The market for medical stocks is gradually recovering, with increased trading activity and positive catalysts such as domestic pharmaceutical companies securing overseas contracts [4] - A new "Pharmaceutical ETF" is set to launch on May 26, which will track the CSI Pharmaceutical Index, focusing on chemical drugs, biological drugs, and traditional Chinese medicine, complementing the existing medical ETF [4] Group 3 - The medical and pharmaceutical sectors have been in a prolonged adjustment period since 2021, with current valuations potentially offering high cost-effectiveness for investors [4]

证券代码：603456 证券简称：九洲药业 公告编号：2025-036 浙江九洲药业股份有限公司 一、美国 FDA 现场检查的相关情况 关于子公司通过美国 FDA 现场检查的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江九洲药业股份有限公司（以下简称"公司"）子公司浙江九洲药物科技 有限公司（以下简称"药物科技"）于 2025 年 3 月 17 日至 2025 年 3 月 21 日期 间接受了美国食品药品监督管理局（以下简称"FDA"）的 cGMP（现行药品生 产质量管理规范）现场检查，检查范围涵盖质量体系、物料、生产、包装与标签、 设备设施、实验室控制六大系统。近日，药物科技收到美国 FDA 签发的现场检 查报告（EIR，Establishment Inspection Report），该报告表明药物科技已通过本 次 cGMP 现场检查，现将相关情况公告如下： 公司名称：浙江九洲药物科技有限公司 检查地点：浙江省杭州钱塘新区临江工业园区经六路 1889 号 检查范围：药物科技涉及产品（非无菌原料药阿替洛尔、枸橼酸 ...

Core Viewpoint - The company, Jiuzhou Pharmaceutical, announced that its subsidiary, Zhejiang Jiuzhou Pharmaceutical Technology Co., Ltd., successfully passed the cGMP on-site inspection by the FDA, which will support its expansion into international markets [1] Group 1 - The FDA inspection took place from March 17 to March 21, 2025, covering six major systems [1] - The successful completion of the cGMP inspection indicates compliance with FDA standards, enhancing the company's credibility in the global market [1] - This achievement is expected to positively influence the company's efforts to expand into regulated international markets [1]

Core Viewpoint - The launch of Mashu Lashawei tablets (brand name: Yisuda) by Qingfeng Pharmaceutical Group represents a significant advancement in the treatment of influenza in China, providing a new therapeutic option for clinicians and addressing the challenges of influenza management [1][2]. Group 1: Product Overview - Mashu Lashawei tablets are the first domestically developed PA inhibitor class influenza innovative drug in China, demonstrating unique advantages in combating drug resistance [2]. - The clinical research data from the Phase III trial indicates that the drug effectively inhibits the RNA polymerase PA subunit of the influenza virus, allowing for rapid symptom relief with a single dose throughout the entire treatment course [2]. Group 2: Clinical Implications - The drug has shown good safety and tolerability, with an overall resistance mutation rate of less than 1%, significantly lower than international counterparts targeting the same mechanism [2]. - Current indications do not cover children under 12 years, who are a high-risk group for influenza, highlighting the urgency for further clinical research to include this demographic [2]. Group 3: Future Directions - Qingfeng Pharmaceutical Group plans to advance clinical research for children under 12, conduct resistance testing, and work on insurance directory inclusion to enhance drug accessibility [2].

Investment Rating - The investment rating for the company is "Buy" (maintained) [6] Core Views - The company is expected to see a recovery in its raw materials and intermediates business by 2025, with steady growth in its CDMO business driven by an increasing number of projects [1][2] - The company's performance in Q1 2025 shows a recovery with revenue of 1.49 billion yuan (up 0.98% year-over-year) and a net profit of 250 million yuan (up 5.68% year-over-year), primarily benefiting from the steady growth of CDMO business orders [1][3] Financial Performance - In 2024, the company achieved revenue of 5.16 billion yuan (down 6.57% year-over-year) and a net profit of 606 million yuan (down 41.34% year-over-year) [1][4] - The gross margin for Q1 2025 was 37.42% (up 3.38 percentage points year-over-year), indicating improved profitability [3] - The company expects EPS for 2025 to be 0.97 yuan, with projected revenues of 5.71 billion yuan and net profits of 935 million yuan [4][12] Business Segmentation - The CDMO segment is projected to generate revenue of 3.87 billion yuan in 2024 (down 5.12% year-over-year), with a growing pipeline of projects including 35 approved projects and 84 in Phase III clinical trials [2] - The raw materials and intermediates segment is expected to generate revenue of 1.16 billion yuan in 2024 (down 8.04% year-over-year), with a gross margin of 20.11% [2] Profitability Outlook - The company anticipates further improvement in profitability in 2025, driven by increased capacity utilization in the CDMO business and stabilization in pricing and demand for raw materials and intermediates [3][4]

Core Viewpoint - Zhejiang Jiuzhou Pharmaceutical Co., Ltd. has successfully completed a share repurchase plan, acquiring 7.736 million shares, which represents 0.86% of the total share capital, with a total expenditure of approximately 101.99 million yuan [1][2]. Group 1: Share Repurchase Plan - The share repurchase plan was first disclosed on March 22, 2025, with an expected repurchase amount between 100 million yuan and 200 million yuan [1]. - The maximum repurchase price was set at 20 yuan per share, and the repurchase period is 12 months from the board's approval [1]. - The repurchased shares will be used for employee stock ownership plans or equity incentive programs [1]. Group 2: Implementation Details - The company initiated the share repurchase on March 31, 2025, and completed it by May 15, 2025 [2]. - The actual repurchase price ranged from 12.36 yuan to 13.90 yuan per share [2]. - The total amount spent on the repurchase was 101.99 million yuan, excluding transaction fees [2]. Group 3: Shareholding Structure - Before the repurchase, the total number of shares was 895,235,828, all of which were unrestricted circulating shares [4]. - After the repurchase, the number of shares held in the repurchase special securities account increased from 5,789,800 to 13,525,800 [4]. - The repurchased shares will be temporarily held in a special account and will not have voting rights or profit distribution rights during the holding period [4]. Group 4: Compliance and Governance - There were no stock trades by major stakeholders, including the controlling shareholder and senior management, during the period from the announcement of the repurchase to the disclosure of the results [3]. - The company confirmed that the execution of the repurchase plan aligns with the previously disclosed details, ensuring compliance with regulations [2].

Core Viewpoint - The company has adjusted its profit distribution plan for the year 2024, proposing a cash dividend of 3.00 yuan per 10 shares, totaling approximately 364.41 million yuan, which represents a significant portion of the net profit attributable to shareholders [1][2]. Group 1: Profit Distribution Plan - The initial profit distribution plan proposed a cash dividend of 0.30 yuan per share, with a total cash dividend amounting to 365.65 million yuan, which was based on the total share capital as of April 10, 2025 [1]. - The adjusted profit distribution plan maintains the cash dividend at 3.00 yuan per 10 shares, with a total cash dividend of approximately 364.41 million yuan, reflecting the company's commitment to uphold the per-share distribution ratio despite changes in total share capital [2]. Group 2: Share Buyback - The company has implemented a share buyback amounting to approximately 99.89 million yuan, which is included in the total cash distribution to shareholders [1][2]. - The total amount for cash dividends and share buybacks combined is approximately 364.41 million yuan, indicating a strategic approach to returning value to shareholders [2].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/3/22 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 12 个月 | | 预计回购金额 | 10,000万元~20,000万元 | | 回购价格上限 | 20元/股 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 实际回购股数 | 773.60万股 | | 实际回购股数占总股本比例 | 0.86% | | 实际回购金额 | 10,199.11万元 | | 实际回购价格区间 | 12.36元/股~13.90元/股 | 证券代码：603456 证券简称：九洲药业 公告编号：2025-034 浙江九洲药业股份有限公司 关于股份回购实施结果暨股份变动的公告 三、 回购期间相关主体买卖股票情况 2025 年 3 月 22 日，公司首次披露了回购股份事项，具体内容详见公司于 2025 年 3 月 22 日在《上海证券 ...